CD8A and hepatocellular carcinoma: A recent report has shown that anti-VEGF therapy could induce CD8+ T cell infiltration in HCC; therefore, immune checkpoint inhibitors combined with bevacizumab (e.g., atezolizumab and bevacizumab) could achieve a good response [25,26,27].